Cardiac MRI for the evaluation of oncologic cardiotoxicity.

ABSTRACT: Cancer therapeutics-related cardiac dysfunction (CTRCD) is a well-established adverse effect resulting from a number of cancer therapeutics. Newer immunotherapy has been associated with cardiomyopathy and myocarditis making comprehensive imaging useful for early recognition. Cardiac MRI (CMR) offers a comprehensive evaluation to detect CTRCD. Established guidelines for monitoring left ventricular ejection fraction for potential cardiotoxicity have recently incorporated CMR. We will review the utility of CMR in contemporary evaluation for potential oncologic cardiotoxicity.

SUBMITTER: Loffler AI 

PROVIDER: S-EPMC6222005 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature